NICE draft guidance does not recommend tucatinib for advanced breast cancer
NICE has today (26 October) published draft guidance for public consultation which does not recommend tucatinib (also called TUKYSA and made by Seagen Inc), in combination with trastuzumab and capecitabine, for some types of breast cancer that has spread.
-
NICE calls for healthcare professionals to use shared decision making best practice to highlight the risks of medicines associated with dependence
NICE is advising doctors, nurses and pharmacists to discuss with patients the risks of prescribing them medicines including opioids, sleeping pills and antidepressants.
-
NICE announces next steps for publication of its guideline on ME/CFS
NICE has today (20 October 2021) announced the next steps for publication of its updated guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS).
-
World Evidence Based Healthcare Day 2021: Learn how a collaboration between NICE and Australian academics helped shape the evidence based rapid COVID-19 guidelines
Online event will lift the lid on how the two organisations worked together during the pandemic
